Completed PHASE2 INTERVENTIONAL 1-arm NCT00512096

Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis

A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis

Sponsor: M.D. Anderson Cancer Center

Conditions Penile Cancer

Interventions Cisplatin Ifosfamide Paclitaxel (Taxol)

Updated 5 times since 2017 Last updated: Jul 27, 2012 Started: Aug 31, 1999 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00512096, this PHASE2 trial focuses on Penile Cancer and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 5 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States